|
Name |
Nonacosane
|
| Molecular Formula | C29H60 | |
| IUPAC Name* |
nonacosane
|
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCCCCCC
|
|
| InChI |
InChI=1S/C29H60/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-29H2,1-2H3
|
|
| InChIKey |
IGGUPRCHHJZPBS-UHFFFAOYSA-N
|
|
| Synonyms |
NONACOSANE; n-Nonacosane; 630-03-5; Octacosane, methyl-; CHEBI:7613; IGL1697BK1; UNII-IGL1697BK1; EINECS 211-126-2; Nonacosane, 99%; MFCD00009356; AI3-36284; CELIDONIOL, DEOXY-; Nonacosane, analytical standard; CHEMBL428955; DTXSID2060884; HSDB 8359; CH3-[CH2]27-CH3; HY-N5127; ZINC6920421; LMFA11000005; AKOS015902539; AS-56220; DB-054368; CS-0032473; FT-0632673; N0167; C08384; P50001; N-BOC-4-NITRO-L-PHENYLALANINE-T-BUTYLESTER; Q151038; DC7C60EC-A78D-4260-BEE6-9249D1D69C33
|
|
| CAS | 630-03-5 | |
| PubChem CID | 12409 | |
| ChEMBL ID | CHEMBL428955 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 408.8 | ALogp: | 15.3 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 26 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 29 | QED Weighted: | 0.1 |
| Caco-2 Permeability: | -5.389 | MDCK Permeability: | 0.00000262 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.062 |
| 30% Bioavailability (F30%): | 1 |
| Blood-Brain-Barrier Penetration (BBB): | 0.003 | Plasma Protein Binding (PPB): | 101.33% |
| Volume Distribution (VD): | 5.424 | Fu: | 0.71% |
| CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.124 |
| CYP2C19-inhibitor: | 0.104 | CYP2C19-substrate: | 0.052 |
| CYP2C9-inhibitor: | 0.014 | CYP2C9-substrate: | 0.977 |
| CYP2D6-inhibitor: | 0.038 | CYP2D6-substrate: | 0.014 |
| CYP3A4-inhibitor: | 0.125 | CYP3A4-substrate: | 0.011 |
| Clearance (CL): | 4.257 | Half-life (T1/2): | 0.006 |
| hERG Blockers: | 0.494 | Human Hepatotoxicity (H-HT): | 0.003 |
| Drug-inuced Liver Injury (DILI): | 0.475 | AMES Toxicity: | 0.009 |
| Rat Oral Acute Toxicity: | 0.012 | Maximum Recommended Daily Dose: | 0.049 |
| Skin Sensitization: | 0.98 | Carcinogencity: | 0.014 |
| Eye Corrosion: | 0.997 | Eye Irritation: | 0.924 |
| Respiratory Toxicity: | 0.178 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000443 | ![]() |
0.966 | D00AOJ | ![]() |
0.689 | ||
| ENC000435 | ![]() |
0.965 | D00STJ | ![]() |
0.432 | ||
| ENC000437 | ![]() |
0.934 | D07ILQ | ![]() |
0.422 | ||
| ENC000401 | ![]() |
0.929 | D00FGR | ![]() |
0.416 | ||
| ENC000381 | ![]() |
0.904 | D0Z5SM | ![]() |
0.376 | ||
| ENC000434 | ![]() |
0.894 | D0Z1QC | ![]() |
0.342 | ||
| ENC000433 | ![]() |
0.859 | D01NTX | ![]() |
0.339 | ||
| ENC001238 | ![]() |
0.856 | D0T9TJ | ![]() |
0.326 | ||
| ENC000716 | ![]() |
0.856 | D0O1PH | ![]() |
0.325 | ||
| ENC000576 | ![]() |
0.850 | D05ATI | ![]() |
0.320 | ||